唾液替代血浆用于晚发型脓毒症新生儿阿米卡星治疗药物监测的可行性研究
该前瞻性单中心观察性可行性研究纳入23例早产和足月新生儿,采集唾液及临床常规残余血浆,用液相色谱-串联质谱定量阿米卡星浓度,并建立 plasma 与唾液整合群体药代动力学模型。蒙特卡洛模拟显示,使用1至5份唾液样本或1至5份血浆样本时,目标达标率分别从77.6%升至79.2%和从79.9%升至83.2%,提示唾液TDM达标率与血浆相当。
要点
- 唾液阿米卡星TDM达标率与血浆样本相当,或可减少新生儿采血负担。
- 唾液隔室一级吸收速率常数k13为0.0345 h⁻¹,个体间变异45.3%。
- 月经后年龄对k13有显著负向协变量效应,指数为-4.3。
核心结论
- 使用唾液样本进行阿米卡星TDM的目标达标率与血浆样本相当,可能对晚发型脓毒症早产儿有益。
研究设计与样本
- 前瞻性单中心观察性可行性研究,纳入23例早产和足月新生儿,每人最多采集8份唾液样本及临床常规残余血浆。
- 采用液相色谱-串联质谱法测定唾液和血浆阿米卡星浓度,并进行群体药代动力学分析以建立整合模型和识别协变量。
主要发现
- 唾液中可检测到阿米卡星,唾液隔室被附加于二室血浆模型。
- 唾液隔室一级吸收速率常数k13为0.0345 h⁻¹,个体间变异为45.3%。
- 一级消除速率常数k30为0.176 h⁻¹。
- 月经后年龄对k13有显著负向协变量效应,指数为-4.3。
- 使用1至5份唾液样本时目标达标率从77.6%升至79.2%,使用1至5份血浆样本时从79.9%升至83.2%。
临床怎么用
- 对于晚发型脓毒症早产和足月新生儿,可考虑使用唾液样本替代血浆进行阿米卡星TDM以减少采血负担。
- 唾液TDM方案可参考1至5份样本的采样策略,其目标达标率与血浆样本相当。
局限性
- 本研究为单中心观察性可行性研究,样本量较小(23例新生儿)。
- 蒙特卡洛模拟基于虚拟代表性新生儿队列,结果需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Amikacin is an aminoglycoside antibiotic that is frequently used for the treatment of neonatal late-onset sepsis, for which therapeutic drug monitoring (TDM) is advised. In order to decrease the TDM associated burden of plasma sampling, a noninvasive TDM method using saliva samples was investigated. METHODS: This was a prospective single-centre, observational feasibility study with 23 premature and term neonates from whom up to 8 saliva samples were collected, together with residual plasma from clinical routine. Amikacin concentrations in saliva and plasma were quantified with liquid chromatography-tandem mass spectrometry. A population pharmacokinetic analysis was performed to develop an integrated pharmacokinetic model of amikacin in plasma and saliva and for the identification of covariates. TDM performance of different sampling regimens was evaluated using Monte Carlo simulations in a fictional cohort of representative neonates (n = 10 000). RESULTS: Amikacin could be detected in saliva and a saliva compartment was appended to a 2-compartment plasma model. First-order absorption (k13 ) of the saliva compartment was 0.0345 h-1 with an interindividual variability of 45.3%. The rate of first-order elimination (k30 ) was 0.176 h-1 . Postmenstrual age had a significant negative covariate effect on k13 , with an exponent of -4.3. Target attainment increased from 77.6 to 79.2% and from 79.9 to 83.2% using 1-to 5 saliva samples or 1-5 plasma samples, respectively. CONCLUSION: TDM of amikacin using saliva samples results in target attainment comparable to plasma samples and may be beneficial for (premature) neonates with late-onset sepsis.
引用
- Samb A, Sinkeler F, Bijleveld YA, et al. Therapeutic drug monitoring of amikacin in preterm and term neonates with late-onset sepsis. Can saliva samples replace plasma samples? Br J Clin Pharmacol. 2023. PMID: 37325890. doi:10.1111/bcp.15823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。